Verrica Pharmaceuticals to Showcase Innovations at Upcoming Conference
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), a key player in the dermatology therapeutics market, is gearing up to present at the Citizens Life Sciences Conference in New York City. This event, scheduled for the first week of May, will feature Jayson Rieger, PhD, MBA, serving as the President and CEO, who is expected to share critical insights on the company’s cutting-edge drug developments aimed at treating skin diseases that require medicinal intervention.
Details of the Citizens Life Sciences Conference
The Citizens Life Sciences Conference is set to take place on May 7–8, providing an excellent opportunity for investors and healthcare professionals to learn more about the breakthroughs in dermatology. On the agenda is a presentation by Dr. Rieger, slated for 3:00 pm ET, where he will discuss the ongoing progress of Verrica’s products and the needs they address within the dermatology market. This conference will be held at the New York Hilton Midtown.
How to Access the Presentation
For those unable to attend in person, there will be a live webcast of Dr. Rieger's presentation available online. Interested participants are encouraged to access it through the official Verrica website or directly from the conference page. Following the live event, a replay of the webcast will be accessible for 90 days, ensuring that all interested parties have the opportunity to catch up on the latest developments in dermatological therapeutics.
About Verrica Pharmaceuticals Inc.
Verrica specializes in the formulation of medications specifically targeting skin diseases. Their flagship product, YCANTH® (VP-102), has garnered attention as the first FDA-approved treatment for molluscum contagiosum, a widespread viral infection that significantly affects children in the United States. This treatment is remarkable because it not only addresses a common yet challenging condition but also continues to represent significant unmet medical needs in dermatology.
Ongoing Developments and Future Directions
Beyond YCANTH® (VP-102), Verrica Pharmaceuticals is advancing other therapies, including one focused on treating common warts, a prevalent dermatological concern. In partnership with Lytix Biopharma AS, they also continue to develop VP-315, which holds promise for the treatment of non-melanoma skin cancers, such as basal cell carcinoma and squamous cell carcinoma. This collaboration is an exciting development for those involved in the oncology sector of dermatology.
The Importance of Engagement in Life Sciences
The Citizens Life Sciences Conference is a pivotal gathering that highlights innovations and the direction of healthcare, especially in specialized fields like dermatology. By participating, Verrica Pharmaceuticals not only heightens visibility among investors but also underscores its commitment to advancing therapies that can make a difference in patients' lives. Engaging in such forums reflects the company’s ethos toward transparency and collaboration within the life sciences community.
Connect with Verrica Pharmaceuticals
For further inquiries, investors can reach out to:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Frequently Asked Questions
What is the primary focus of Verrica Pharmaceuticals?
Verrica Pharmaceuticals focuses on developing dermatology therapeutics aimed at treating skin diseases requiring medical interventions.
When is the Citizens Life Sciences Conference scheduled?
The Citizens Life Sciences Conference is scheduled for May 7–8, with Verrica's presentation set for 3:00 pm ET on May 7.
How can I access the conference presentation from Verrica?
The presentation can be accessed via a live webcast available on Verrica’s official website and the conference page.
What is the significance of the YCANTH® (VP-102) product?
YCANTH® (VP-102) is significant as it is the first FDA-approved treatment for molluscum contagiosum, affecting millions, primarily children.
Which companies is Verrica collaborating with for its product development?
Verrica has entered into a collaboration with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers.
